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Abstract
Adult bone marrow stroma contains multipotent stem cells (BMSC) that are a mixed population of mesenchymal and
neural-crest derived stem cells. Both cells are endowed with in vitro multi-lineage differentiation abilities, then constituting
an attractive and easy-available source of material for cell therapy in neurological disorders. Whereas the in vivo integration
and differentiation of BMSC in neurons into the central nervous system is currently matter of debate, we report here that
once injected into the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, pure populations of
either bone marrow neural crest stem cells (NCSC) or mesenchymal stem cells (MSC) survived only transiently into the
lesioned brain. Moreover, they do not migrate through the brain tissue, neither modify their initial phenotype, while no
recovery of the dopaminergic system integrity was observed. Consequently, we tend to conclude that MSC/NCSC are not
able to replace lost neurons in acute MPTP-lesioned dopaminergic system through a suitable integration and/or
differentiation process. Altogether with recent data, it appears that neuroprotective, neurotrophic and anti-inflammatory
features characterizing BMSC are of greater interest as regards CNS lesions management.
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Introduction
The treatment of neurological disorders represents a critical
issue in clinical research, since no complete functional recovery
can be achieved with current therapeutic means, despite
symptomatic improvements. Indeed, whereas restricted brain
areas still house cells competent to generate newborn neurons in
adulthood [1,2], this limited neurogenesis does not seem to be
sufficient to enable neuronal regeneration in cases of lesions of the
central nervous system. Therefore, other sources of neural cells
have to be considered in a cell therapy objective. Stem cells are
characterized as cells endowed with continuous self-renewal ability
and pluri- or multipotentiality [3], and could consequently give
rise to a wide panel of cell types, including neural cells. Indeed,
while neurons have already been successfully generated from
embryonic stem cells (ES) [4,5] or induced pluripotent stem cells
(iPS) [6,7], the use of adult somatic stem cells definitely remains of
significant interest regarding technical, ethical and immunological
issues concerning cell transplantation for brain-related diseases. In
this regard, bone marrow stromal cells (BMSC) represent an
important source of easily-accessible multipotent cells to use in a
cell therapy purpose [8].
Numerous studies already described cell therapy experiments
using BMSC and explored their neuronal plasticity in vivo [9–11].
However, result discrepancies appeared in those studies, which
could mainly reside in the lack of exact phenotypic characteriza-
tion of BMSC, due to the absence of specific membrane markers
and non-standardized culture methods. Consequently, several
groups described BMSC with major different phenotypes:
Verfaillie’s group described a rare population of cells in human
BM stroma as mesodermal adult progenitor cells [12,13];
D’Ippolito and collaborators cultured cells in low oxygen tension
and characterized marrow isolated adult multilineage inducible
cells [14,15]; whereas a lot of other groups kept the mesenchymal
stem cell (MSC) concept as defined by Pittenger et al. [16]. In
addition to the phenotypic differences of BMSC which are
inherent to culture settings, it has been demonstrated that BMSC
are constituted by a mixed population of cells arising from
different embryonic lineages. Indeed, although adult BMSC were
commonly considered to be of mesodermal origin [17], several
studies have conclusively shown that some adult BMSC derive
from the neural crest [8,18–21].
The main objective of this study was consequently to specifically
analyze the capacity of in vivo differentiation of the two distinct
populations of BMSC: mesenchymal stem cells (MSC) and neural
crest stem cells (NCSC), both isolated from adult bone marrow
and recently characterized by Wislet-Gendebien et al. [21,22],
when injected into lesioned brain. Indeed, we know that bone
marrow NCSC are present in low proportion inside primary
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BMSC cultures compared to the MSC [22]. Consequently, a graft
of pure bone marrow NCSC could lead to different results than
observed with BMSC and could be able to restore brain lesions
through a neural differentiation process in a larger extent, due to
their neural crest developmental origin. We therefore grafted
NCSC and MSC pure populations into the brain of mice
characterized by dopaminergic nigrostriatal pathway lesions
(mimicking the dopaminergic cell loss in advanced stages of
Parkinson’s disease) induced by previous 1-methyl-4-phenyl-2,3,5-
tetrahydropyridine hydrochloride (MPTP-HCl) injections. We
then investigated neural differentiation events and downstream
effects on the nigrostriatal pathway integrity, in order to evaluate




Wnt1-Cre/R26R-LacZ double transgenic mice were used to
isolate NCSC and MSC clones from adult bone marrow stromal
cells cultures [22]. 12 to 16-week-old wild type C57BL/6J mice
(The Jackson Laboratory, Bar Harbor, ME, USA) were used as
recipient mice for graft experiments. Animals were bred at the
University of Lie`ge Central Animal facility and experiments were
performed in accordance with the rules set by the local animal
ethics committee (ethical permit 1038) as well as the Swiss
Academy of Medical Sciences.
MPTP Administration
Five days before the cell graft experiment, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine hydrochloride (MPTP-HCl) (Sigma-
Aldrich, St-Louis, MO, USA) is suspended in sterile PBS solution
at a concentration of 5 mg/mL. Mice received four intraperito-
neal injections of 20 mg/kg MPTP-HCl, at two hours interval
(100 to 120 mL for 25 to 30 g-weight mice), as already described in
[23,24], triggering acute bilateral dopaminergic neurons cell
death.
Cell Culture Procedures and Clonal Selection
Bone marrow cells from adult (8–10 week-old) Wnt1-Cre/R26R-
LacZ mice were obtained from femoral and tibial bones by
aspiration and were resuspended in MesenCult Medium (Mesen-
Cult, Stem Cells Technologies, Grenoble, France). After 24 hours,
non-adherent cells were removed. After reaching confluence,
BMSC were resuspended using 0,05% trypsin-EDTA (Life
Technologies, Carlsbald, CA, USA) and then sub-cultured
(750,000 cells/25 cm2) at 37uC, in a 95% O2/5% CO2
atmosphere. For clonal selection, passage 5 BMSC were seeded
in a 96 well plate (Thermo Fisher Scientific, Langenselbold,
Germany) at a mean dilution of 0.7 cell/well, in MesenCult
Medium. At confluence, cells were dissociated with 0,05% trypsin-
EDTA and subcultured in the same conditions.
Genomic Validation of Wnt1-CRE/R26R-LacZ
Recombination
DNA was isolated from NCSCmix and MSCmix using the
QIAamp DNA Mini Kit extraction protocol (Qiagen, German-
town, MD, USA). Briefly, cells were incubated at 56uC with
proteinase K in a lysis buffer for 10 min, then genomic DNA was
purified through several silica-membrane-based steps (see manu-
facturer’s instructions). DNA amount was then calculated via a
NanoDrop spectrophotometer (Thermo Scientific). Afterwards,
DNA sequences of interest were amplified by polymerase chain
reaction by mixing 500 ng of genomic DNA with Taq Polymerase
(Promega) and specific primers (PGK-Neo: For-ATGGATTG-
CACGCAGGTTCTCC; Rev-CAGAAGAACTCGTCAA-
GAAGGC and actin: For-ATCTTGATCTTCATGGTGC-
TAGG; Rev-TGTTACCAACTGGGACGACATGG) in a
T3000 thermocycler (Biometra, Go¨ttingen, Germany).
Cell Preparation and Transplantation
Just before the transplantation, two cell solutions containing
respectively 5 NCSC clones and 5 MSC clones in equal numbers
were prepared. Whereas NCSCmix were already traceable thanks
to their b-galactosidase activity, we needed to label MSCmix with
Cell Tracker Green (CTG) (Life Technologies) to allow their
traceability in vivo. Mice were anesthetized with 100 mg/kg of a
solution containing equivalent volumes of xylazine (Rompun,
Bayer, Belgium) and ketamine (Ketalar, Pfijzer, Belgium). They
were then placed into a stereotaxic frame (Benchmark, MyNeur-
oLab.com) and received one injection of 56104 cells suspended in
2 mL PBS (Life Technologies) in the right striatum (0,5 mm
anterior, 2 mm lateral and 3 mm ventral, with respect to bregma).
The intracerebral injection was performed using a Hamilton’s 5 ml
syringe, coupled with a 26-gauge needle. The needle was left in
place for few minutes before being retracted, to avoid reflux along
the injection track. After the surgery, mice were placed under a
warm lamp until their complete awakening.
Brain Processing
At different delays following cell transplantation, animals were
anesthetized with pentobarbital and sacrificed by intracardiac
perfusion of ice-cold PBS, followed by paraformaldehyde (PFA)
4% (in PBS 0,1 M), at. Skulls were dissected and brains were
immediately removed, post-fixed for 2 hours at 4uC in the same
fixative then immersed overnight in a solution of sucrose 20% (in
PBS 0,1 M). They were frozen by slow immersion in isopentane
cooled on dry-ice. Coronal 14 mm-sections were cut using a
cryostat, mounted on positively charged slides, and stored in
220uC for further experiments (30 slides covering the entirety of
the striatum and 10 slides covering the entirety of the midbrain).
DNA Extraction from Striatal Slices and PCR Validation of
Survival Rate Evaluation
DNA was extracted from 14 mm-striatal slices (after 220uC
storage) using the PrepFiler Forensic DNA Extraction Kit (Life
Technologies). Right striatum was microdissected on about 10
slices and then scraped into a 1,5 mL microcentrifuge tube. After
lysis with proteinase K and heat/shake treatment, genomic DNA
was bound to PrepFiler Magnetic Particles and then eluted in
order to amplify sequences of interest by PCR (See Genomic
validation of Wnt1-CRE/R26R-LacZ recombination section).
Immunostainings
Briefly, 14-mm brains slices (or cells on coverslips) were
incubated for 1 hour with 10% normal donkey serum in PBS
0,1 M (supplemented with 0,3% Triton X-100 for intracellular
antigens). For specific immunofluorescent staining, anti-nestin
(1:300, NB100-1604; Novus Biologicals, Littleton, CO, USA),
anti-bIII-tubulin (1:1000, MMS-435P; Covance, Princeton, NJ,
USA), anti-GFAP (1:1000, Z0334; Dako, Glostrup, Denmark),
anti-TH (1:250, ab112; Abcam, Cambridge, UK), anti-Sca-1
(1:100, ab25195; Abcam), anti-Fzd-4 (1:100, MAB194; R&D
System, Minneapolis, MN, USA) and anti-CD24 (1:200, ab64064;
Abcam) were diluted in PBS 0,1 M overnight at 4uC. After three
PBS washes, brains sections were incubated with FITC or
Rhodamine Red X-conjugated secondary antibodies (1:500;
NCSC and MSC Graft in Acute MPTP-Lesioned Mice
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Jackson Immunoresearch Laboratories, West Grove, PA, USA) for
1 hour at room temperature. Nuclei were then counterstained
with Hoescht 33342 (Molecular Probes, Life Technologies) and
finally mounted in Q Path Safemount (Labonord, Templemars,
France).
The same steps and panel of primary antibodies were used for
immunochemistry, but stainings were acquired using peroxydase-
coupled secondary antibodies (1:500, Dako) and diaminobenzidine
revelation.
Image acquisition and analysis were performed using a Zeiss
AxioImager Z1 epifluorescent microscope (Zeiss, Zaventem,
Belgique) coupled with FluoView software (Olympus, Artselaar,
Belgique), and Olympus AX-70 microscope (Olympus) coupled
with AnalySIS software (Olympus). The digitized images were
adjusted for brightness and contrast, color-coded, and merged,
when appropriate, using the NIH program ImageJ (Wayne
Rasband, National Institute of Mental Health, Bethesda, MD,
USA).
Other Stainings
X-gal staining. Brains sections were incubated for 2 hours in
PBS supplemented with Tris (pH 7,4) 20 mM, MgCl2 2 mM,
0.02% NP-40, 0.01% Na-deoxycholate, K3Fe(CN)6 5 mM (Sig-
ma-Aldrich), K4Fe(CN)6 5 mM (Sigma-Aldrich) and 1-methyl-3-
indolyl-beta-Dgalactopyranoside 1 mg/ml (Sigma-Aldrich) sus-
pended in DMSO. The reaction was stopped by PBS washes.
Carazzi hematoxylin coloration. Dry brain sections were
placed in denatured ethanol and slightly heated for approximately
4 minutes, then were washed three times in milliQ water, before
an incubation of 10 minutes in Carazzi hematoxylin. After three
washes in water, sections were finally mounted with Q Path
Safemount (Labonord).
Quantification of Cell Survival and Number of Neurons in
the SN and VTA
Cell survival was quantified as followed: To evaluate the
number of NCSCmix in the brains at each time point post-
transplantation, X-gal staining was performed on 4 slides
containing striatal slices (4 slides covering the 30 slides : e.g. slide
1–10–20 - 25). Nuclei were counterstained with Hoescht, and after
superposition of X-gal/Hoescht staining, X-gal positive nuclei
were counted in each striatal sections on the slides. We then
normalized the number of X-gal positive nuclei for all the 30
sections covering the entirety of striatum, and expressed this
number in % regarding the 56104 cells that were initially injected.
To evaluate the number of MSCmix in the brains at each time
point post-transplantation, co-localization of Cell Tracker Green
and Hoescht was used and the same countings and normalizations
were performed.
To evaluate the nigrostriatal pathway integrity, SNpc and VTA
neurons were counted as previously described in the followed
MPTP-administration protocol [23]. Our neuronal counts were
expressed as mean number of neurons per representative
mesencephalic plane. For each mouse, sections covering the entire
rostrocaudal axis of the mesencephalon were analyzed. The mean
number of neurons for each representative mesencephalic plane
was obtained by averaging the number of neurons counted from
both right and left SNpc or VTA areas, respectively.
Statistical Analysis
Data were analyzed statistically using Statistica 10 program
(StatSoft, Tulsa, OK, USA). Results are reported as mean 6
standard error of mean, with the n described as the number of
mice in each group. Level of statistical significance was set at
p,0.05.
Results
Clonal Selection of NCSC and MSC from Adult Bone
Marrow
Since we previously demonstrated that neural crest stem cells
were mainly composed of nestin-positive cells [22] and that the
number of nestin-positive cells increased with the number of
passages [25], we decided to perform clonal selection of NCSC
and MSC starting from passage 5, which should theoretically give
us equal chances to isolate NCSC or MSC. Single cell BMSC were
placed in a 96-wells plate in MesenCult medium allowing 1.2% of
cells to proliferate. NCSC clones or MSC clones were then pooled
together creating two distinct and pure population: NCSCmix and
MSCmix. We first verified that cells in NCSCmix were effectively
derived from initial embryonic neural crest cells that underwent
Cre-Lox recombination, conversely to MSC clones that were not
neural crest-derived (Fig. 1 A–B). NCSCmix (b-galactosidase-
positive cells; Fig 1.C) and MSCmix (b-galactosidase-negative cells;
Fig 1.D) were then characterized in vitro. As previously described
[22], NCSCmix were Sox10-positive (Fig 1.D), nestin-positive
(Fig. 1.E) and p75NTR-positive (Fig. 1.F) while MSCmix were
Sox10-negative (Fig. 1.L), less than 15% were nestin-positive
(Fig 1.M) and weakly p75NTR-positive (Fig. 1.N). MSCmix also
expressed Fzd-4 (Fig. 1.Q), Sca-1 (Fig. 1.O) and CD24 (Fig. 1.P)
while NCSCmix were only positives for Fzd-4 (Fig. 1.I). Addition-
ally, bIII-tubulin positive cells were observed in NCSCmix when
cultivated in Mesencult medium (without any differentiation
protocol, Fig. 1.J). At the opposite, no bIII-tubulin positive cells
were observed among MSCmix (Fig. 1.R). However, NCSCmix and
MSCmix were both negative for more mature or specific neuronal
markers like MAP2ab or TH and for GFAP (data not shown). We
then decided to characterize NCSCmix and MSCmix differentiation
and therapeutic abilities in vivo using the MPTP mouse model.
MPTP Mouse Model Validation
In order to verify MPTP-injection impact on nigrostriatal
system (classically affected in Parkinson’s disease) and validate our
experimental model, we quantified the number of dopaminergic
neurons by immunostaining of tyrosine hydroxylase (TH) (limiting
enzyme in dopamine synthesis). As observed on Fig. 2.A, a drastic
decrease in TH-positive fibers in the entire striatum was observed
in MPTP-treated animals compared to control (.95%). At the
midbrain level, TH-positive cell bodies in the Substantia Nigra pars
compacta (SNpc) of MPTP-treated mice were quantified
(45,9365,86 cells per representative mesencephalic plane, n= 5)
and revealed a significant decrease (60%) of the number of cells
compared to the control condition (129,40610,50 TH-positive
neurons per representative mesencephalic plane; n= 5; One-way
ANOVA, p,0,001; Fig. 2.A–B). Ventral tegmental area (VTA)
provides an internal control zone: VTA dopaminergic neurons
were affected by MPTP in a lesser extent than SNpc neurons [26],
and the difference between controls and MPTP-treated animals
was not significant, attesting of MPTP specificity for SNpc neurons
(One-way ANOVA, p.0,05). Those results were consistent with
already published studies [23] (Fig. 2.A–B).
NCSCmix and MSCmix Survival Rate
NCSCmix and MSCmix were injected in mice striatum 5 days
post-MPTP injection. Surviving cells were quantified after 3, 7, 14,
28 and 70 days following cell graft, on all brain sections by
counting nuclei co-localizing with X-gal staining or Cell Tracker
NCSC and MSC Graft in Acute MPTP-Lesioned Mice
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Figure 1. In vitro characterization of NCSCmix and MSCmix, isolated from adult Wnt1-Cre/R26R-LacZ mouse bone marrow. BMSC were
harvested from double-transgenic Wnt1-CRE/R26R-LacZ mouse bone marrow (A). Amplification of the PGK-Neo cassette confirmed that NCSCmix
NCSC and MSC Graft in Acute MPTP-Lesioned Mice
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Green (CTG) (for respectively grafted NCSCmix and MSCmix). We
first observed that transplanted cells (both NCSCmix and MSCmix)
staid tightly confined to the engraftment site, without any evident
signs of migration through the brain tissue: no grafted cells were
recovered into the lesioned SNpc or anywhere else inside the
brain. As observed on Fig. 3.B, around 10% of NCSCmix survived
up to 7 days post-graft and 3% up to 14 days. After that delay, less
than 1% of NCSCmix were detected. Similar results were observed
for MSCmix as the mean survival rate of grafted cells was evaluated
at 10% after 3 days. The survival rate at 7 days post-graft was
decreased to 3%, and no grafted MSC were detected at 14 days
post-graft. Control mice (injected with saline instead of MPTP)
were also grafted with the same number of NCSCmix or MSCmix
and we observed that the cells also disappeared within a 28 days
timeframe (Fig. S1). As the stability of CTG fluorescence with time
could be questioned, we confirmed by PCR that the cells were
totally gone from the brain starting from 14 days after transplan-
tation. In that purpose, we microdissected transplanted striatum
slices and we showed that no PGK-Neo signal was observed
starting from 14 days post transplantation (in saturating condi-
tions) (Fig. 3.B).
Phenotypic Characterization of Grafted MSCmix/NCSCmix
At each time point post-transplantation, grafted NCSCmix and
MSCmix were tested for nestin, glial fibrillary acidic protein
(GFAP), bIII-tubulin, and tyrosine hydroxylase (TH) immunore-
activity. Similar results than the one observed in vitro were
recovered as transplanted NCSCmix expressed nestin (Fig. 4.E)
while MSCmix did not (Fig. 4.I) [22], and both types of cells were
GFAP-negative (Fig. 4.F,J). Regarding bIII-tubulin expression,
specific co-localization was more difficult to appreciate since the
environing brain tissue was entirely immunoreactive. However,
only few positive cells were observed for NCSCmix (Fig 4.G), and
no evidence was noticed for MSCmix (Fig. 4.K). Finally, no grafted
cell (neither NCSCmix nor MSCmix) differentiated into functional
dopaminergic cells, as attested by their negativity for TH marker
(Fig. 4.H,L and Fig. S2). According to those results, it appeared
that the in vivo environment (MPTP-lesioned striatum) did not
induce any modification in the phenotype of transplanted
NCSCmix and MSCmix.
Effects of Cell Graft on MPTP-induced Lesions
We evaluated the integrity of nigro-striatal pathway thanks to
the immunolabelling of tyrosine hydroxylase (TH). As already
mentioned, the number of TH-positive neurons in the SNpc of
underwent recombination, conversely to MSCmix (B). NCSCmix were b-galactosidase positive (blue, C), whereas MSCmix were not (blue, K)
(Hematoxylin–stained nuclei). NCSCmix expressed neural crest-associated proteins Sox10 (green, D), Nestin (green, E) and p75NTR (green, F). MSCmix
were Sox10-negative (green, L), weakly p75NTR-positive (green, N), and only a small proportion (,15%) of cells expressed nestin (green, M). MSCmix
also expressed Sca-1 (green, O) and CD24 (green, P) while NCSCmix did not (green, G-H), and both types of cells were positive for Fzd-4 (green, I-Q). In
NCSCmix, some b-tubulin-expressing cells were detected (in MesenCult medium) (green, J), but no cell in the MSCmix was b-tubulin-positive in those
conditions (green, R) (DAPI-stained nuclei). (Scale bars = 30 mm).
doi:10.1371/journal.pone.0064723.g001
Figure 2. Validation of the MPTP mouse model of dopaminergic cell degeneration. A. Tyrosine hydroxylase (TH) immunostaining (brown,
hematoxylin-stained nuclei) of dopaminergic fibers in the striatum and neurons in the midbrain of control and acute MPTP-treated mice. B. Number
of TH-positive cell bodies per representative mesencephalic plane (Mean6 SEM). The number of dopaminergic neurons in the SNpc of MPTP-treated
mice is significantly decreased compared to control (p,0,001, One-way ANOVA), while the VTA dopaminergic neurons are not strongly affected
(p.0,05, One-way ANOVA). (Scale bars = 500 mm).
doi:10.1371/journal.pone.0064723.g002
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Figure 3. Intrastriatal transplantation of MSCmix/NCSCmix in MPTP mice and survival rate of grafted cells at 3, 7, 14, 28 and 70 days
after transplantation. A. Experimental design of the lesion and transplantation experiment. Adult C57Bl/6J male mice were injected with MPTP
following the ‘‘classical’’ acute regimen. Five days after MPTP treatment MSCmix/NCSCmix were injected into the right striatum of mice (MSCmix were
first stained with Cell Tracker Green in order to be detected in vivo). Survival rate evaluation and phenotypic characterization were performed at
different delays post-graft. B. The number of surviving NCSCmix in the right striatum (blue X-gal staining and purple Hematoxylin-stained nuclei) can
reach 15% in the first week after transplantation, then the cells begin to disappear and after 4 weeks, we only observe a mean survival rate of 1%.
Results are expressed in %, according to the 56104 injected cells (Mean 6 SEM). MSCmix (green CTG staining, blue DAPI-stained nuclei) seem to
NCSC and MSC Graft in Acute MPTP-Lesioned Mice
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MPTP-treated animals was decreased for more than 50%,
compared to control animals, and the dopaminergic fibers in the
striatum nearly completely disappeared (Fig. 5.A). After 28 and
even 70 days following the cell transplantation, no improvement in
striatal TH staining was observed in MPTP-injected mice in both
conditions (NCSCmix-grafted group, Fig. 5.B and MSCmix-grafted
group, Fig. 5. C). Similarly, we did not see any significant
modification in the number of host TH-positive cell bodies into the
SNpc of MPTP mice that received cell grafts (Fig. 5.D) (Kruskal-
Wallis ANOVA, p.0,05).
Discussion
Adult bone marrow stromal cells (BMSC) are of significant
interest in cell therapy, regarding their accessible location, low
immunogenicity and multipotentiality. Previous studies already
described their neural differentiation abilities [27,28], then
confirming their potential use in the treatment of neurological
diseases. Moreover, the presence of neural crest derived cells into
the adult bone marrow stroma [21,22] raised new hopes to obtain
functional neurons from autologous adult stem cells [8]. Recently,
a clinical trial described unilateral transplantation of autologous
whole BMSC population into the subventricular zone (SVZ) of PD
patients, and reported reserved clinical improvement with no
adverse effects, such as tumor formation [29,30]. Whereas those
results were based on clinical observations and Unified Parkinson’s
disease Rate Scale scores, the mechanisms underlying the reported
improvements are completely unknown.
To the light of those observations, the main objective of this
study was to determine if bone marrow neural crest stem cells
(NCSC) were responsible for the positive impact of bone marrow
stromal cells in several PD models rather than mesenchymal stem
cells (MSC). In this study, we addressed the aspect of neural
differentiation abilities of pure NCSC or MSC populations by
directly injecting those cells into the lesioned brain. In this
purpose, the model we selected was an acute lesion of dopami-
nergic system, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) injection [23,31,32]. Consequently, cells were
grafted five days after MPTP injection in order to pass up ongoing
cell death and acute inflammatory events [33–35], with the aim of
disappear more rapidly than NCSCmix, since no cells were observed starting from 14 days. (n$3 for each group, at each delay post-transplantation).
As CTG relevancy might be questioned, the temporary survival of cells was confirmed by PCR amplification of the PGK-Neomycin cassette in grafted
MSCmix. (CC =Corpus callosum; LV = Lateral ventricle; Scale bars = 500 mm).
doi:10.1371/journal.pone.0064723.g003
Figure 4. In vivo characterization of brain-injected NCSCmix and MSCmix. All cells were implanted in the correct brain site, in each mouse
that was included in the study. Transplanted NCSCmix were detected by X-gal staining (blue) and MSCmix were identified thanks to CTG staining
(green). Grafted cells conserved their in vitro phenotype, whatever the delay post-transplantation : NCSCmix were nestin-positive (brown, A) whereas
MSCmix were not (red, I). No cells did differentiate into GFAP-positive cells (NCSCmix, brown, F; MSCmix, red, J). Only few positive cells in NCSCmix were
bIII-tubulin-positive (brown, G), and no specific positivity was noticed for MSCmix (red, K). Finally, grafted cells were negative for TH (NCSCmix, brown, F;
MSCmix, red, J). Nestin and GFAP staining (brown or red) are detected around the transplanted cells and are linked with injection-induced
inflammation (n$3 for each group, at each delay post-transplantation). Scale bars = 25 mm.
doi:10.1371/journal.pone.0064723.g004
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confirming if a potential enhancement was properly due to
phenotypic plasticity and neural differentiation of injected cells. In
those conditions, neither NCSC nor MSC survived for more than
28 days into the lesioned brain, neither underwent phenotypic
modifications compared to their in vitro state before graft.
Therefore, it wasn’t surprising not to observe any enhancement
in nigro-striatal pathway integrity, suggesting that NCSC and
MSC were not able to successfully differentiate into neural cells
and to integrate and connect with host neurons in acute MPTP-
treated mice.
Discrepancies of our observations with previous studies [36]
could be justified regarding the chronic MPTP-injection protocol
that leads to completely different degeneration kinetics [37].
Indeed, acute-MPTP mouse model do not reflect a real
phenomenon of progressive degeneration, we might miss several
events that could prompt grafted cells to adapt their phenotype.
On the other hand, grafting stem cells in chronic-MPTP mice
would be trickier to characterize, as both neuroprotective and
neurorestorative events could simultaneously occur.
Nonetheless, our results reinforce the current controversy on
BMSC neural differentiation ability. Indeed, whereas loads of
Figure 5. Evaluation of NCSCmix and MSCmix graft consequences on the number of host TH-positive neurons in MPTP-induced
dopaminergic lesions. A. Effect of MPTP on the integrity of dopaminergic nigro-striatal pathway (at 28 days post-MPTP treatment). B. NCSCmix
graft in MPTP-treated mice. No increase in TH-positive (brown) striatal dopaminergic fibers and TH-positive cell bodies in the SNpc is observed, at
28 days as well as 70 days post- NCSCmix transplantation. C. The same observations were carried out after MSCmix transplantation. D. Number of TH-
positive cell bodies in the SNpc of MPTP-treated mice that were transplanted with NCSCmix/MSCmix (p.0,05; Kruskall-Wallis ANOVA). Scale
bars = 250 mm.
doi:10.1371/journal.pone.0064723.g005
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papers describe in vitro specific neural proteins expression in
BMSC after various neural induction protocols [38–41], few data
provide convincing evidence for a neuron-specific electrophysio-
logical signature of the differentiated cells, namely the elicitation of
action potentials [42]. Moreover, the expression of neural specific
proteins fails to characterize authentic functional and mature
neurons, as some neural markers are already observed in primary
cultures (without any differentiation protocols) [43,44] and even
after mesenchymal differentiation [45].
Concerning preclinical cell therapy experiments on PD animals
models, neural differentiation-based therapy protocols were
performed using stem cells from Wharton’s Jelly [46], dental pulp
[47] and bone marrow [9,48] that underwent various culture
conditions before being transplanted in 6-hydroxydopamine (6-
OHDA)-treated rats. Behavioral and pathological enhancements
were observed in most of the studies, but the underlying
mechanisms were not sufficiently detailed, and no evidence for
an appropriate integration into the lesioned central nervous system
(CNS) was observed. Conversely, significant improvements were
observed in PD animal models that were transplanted with BMSC
without any pre-differentiation step. In those conditions, no sign of
neural differentiation was properly observed. Still, beneficial
effects and rescue of dopaminergic neurons were noticed and
mainly associated with neuroprotection [49,50], trophic support
(i.e. glial cell line-derived neurotrophic factor (GDNF) or
epidermal growth factor (EGF) secretion) [50,51] or anti-
inflammation (attenuation of blood-brain barrier damages,
microglia inactivation) [52]. Moreover, BMSC graft induced
proliferation and migration of endogenous SVZ neuroblasts in two
PD animal models [50,53].
As regards the recent data about PD models and BMSC-based
cell therapy, it appears that neural differentiation might not be
responsible for physiopathological and clinical recoveries that are
observed after BMSC transplantation in PD experimental models.
Indeed, no evidence for in vivo functional neuronal replacement
and CNS integration has been provided so far. Our results
confirmed that bone marrow NCSC (in a pure population) are not
any more competent than pure MSC nor whole BMSC to
differentiate into neurons and integrate the damaged dopaminer-
gic system. Altogether, it looks like adult BMSC are not a prime
option for cell replacement therapies in the context of Parkinson’s
disease. However, neuroprotective, neurotrophic and anti-inflam-
matory features characterizing BMSC are of greater interest as
regards CNS lesions management, and still need to be fully
characterized [54].
Supporting Information
Figure S1 Survival rate of grafted cells at 3, 7, 14, 28 and
70 days after transplantation of MSCmix/NCSCmix in
MPTP and control mice. A. In MPTP mice, the number of
surviving NCSCmix in the right striatum (blue X-gal staining and
purple Hematoxylin-stained nuclei) can reach 15% in the first week
after transplantation, then the cells begin to disappear and after 4
weeks, we only observe a mean survival rate of 1%. In control
mice, even if the number of surviving cells is higher at 3 and 7 days
post-graft, the survival rate also decreases to 1% after 28 days. B.
MSCmix (green CTG staining, blue DAPI-stained nuclei) seem to
disappear more rapidly than NCSCmix, since no cells were
observed starting from 14 days, in both MPTP and control mice.
C. Number of grafted cells that were recovered in mice brains at
different delays post transplantation (Mean6 SEM) (CC=Corpus
callosum; LV=Lateral ventricle; Scale bars = 500 mm).
(TIF)
Figure S2 Tyrosine hydroxylase staining of brain-in-
jected NCSCmix, at different delays post transplantation.
Transplanted NCSCmix were detected by X-gal staining (blue).
Grafted cells were negative for TH (brown) at 3, 7, 14 and 28 days
after the cell injection (n$3 for each group, at each delay post-
transplantation). (Scale bars = 100 mm).
(TIF)
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